Patent Exclusivity Health Checks for Biologics: Are Your U.S. Patents Ready to Maximize ROI?

As part of the Strafford Publications’ webinar series, Finnegan partners Paul Barker, Mark Feldstein, and Amanda Murphy will join the panel discussion on the essentials of patent exclusivity that are in critical need of independent checking. The panel will discuss crucial health checks on U.S. patent exclusivity for biologics in Phase II efficacy trials and proceedings through large scale randomized Phase III clinical trials, submission of the BLA, and subsequent approval and marketing. For more information, or to register, please see Strafford’s website.